IMU got a great deal licensing azer-cel from Precision.
Imugene: - Maximum US$227 short term & performance based payments. - Global oncology rights. - Lease of staffed manufacturing plant.
TG Therapeutics: - Maximum US$305.5 short term & performance based payments. - Global autoimmune diseases & non-cancer indications. - NO lease of staffed manufacturing plant.
I agree with Taureanbull that there probably isn't another azer-cel plant at the moment.
If so, there would be an agreement for IMU to supply drug at an agreed upon price.
I'd imagine this would be necessary to enable Precision to licence azer-cel for non oncology indications, as it recently did to TG Therapeutics for autoimmune diseases & other non-cancer indications.
Hence, Gocart received the response, '...Imugene will provide TG Therapeutics with drug at an agreed upon price...'
This is most likely referring to a price agreed prior to 16/08/23, the date of IMU's announcement to the ASX.
IMU Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)